110 related articles for article (PubMed ID: 19909771)
1. Systemic administration of the potential countermeasure huperzine reversibly inhibits central and peripheral acetylcholinesterase activity without adverse cognitive-behavioral effects.
Myers TM; Sun W; Saxena A; Doctor BP; Bonvillain AJ; Clark MG
Pharmacol Biochem Behav; 2010 Jan; 94(3):477-81. PubMed ID: 19909771
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
[TBL] [Abstract][Full Text] [Related]
3. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment.
Ye JW; Cai JX; Wang LM; Tang XC
J Pharmacol Exp Ther; 1999 Feb; 288(2):814-9. PubMed ID: 9918593
[TBL] [Abstract][Full Text] [Related]
4. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase.
Haigh JR; Johnston SR; Peppernay A; Mattern PJ; Garcia GE; Doctor BP; Gordon RK; Aisen PS
Chem Biol Interact; 2008 Sep; 175(1-3):380-6. PubMed ID: 18572153
[TBL] [Abstract][Full Text] [Related]
5. Time Course, Behavioral Safety, and Protective Efficacy of Centrally Active Reversible Acetylcholinesterase Inhibitors in Cynomolgus Macaques.
Hamilton LR; Schachter SC; Myers TM
Neurochem Res; 2017 Jul; 42(7):1962-1971. PubMed ID: 27900576
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds.
Eckert S; Eyer P; Mückter H; Worek F
Biochem Pharmacol; 2006 Jul; 72(3):344-57. PubMed ID: 16780806
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cognitive and biochemical effects of low-level exposure to sarin in rhesus and African green monkeys.
Genovese RF; Oubre JL; Jakubowski EM; Fleming PJ; Saxena A; Rockwood GA; Tipparaju P; Willmore CB
Toxicology; 2007 Feb; 231(1):11-20. PubMed ID: 17126468
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Liang YQ; Tang XC
Neurosci Lett; 2004 May; 361(1-3):56-9. PubMed ID: 15135892
[TBL] [Abstract][Full Text] [Related]
9. Acute behavioral toxicity of pyridostigmine or soman in primates.
Blick DW; Murphy MR; Brown GC; Yochmowitz MG; Fanton JW; Hartgraves SL
Toxicol Appl Pharmacol; 1994 Jun; 126(2):311-8. PubMed ID: 8209384
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats.
Liang YQ; Tang XC
Acta Pharmacol Sin; 2006 Sep; 27(9):1127-36. PubMed ID: 16923332
[TBL] [Abstract][Full Text] [Related]
11. Reversible inhibition of acetylcholinesterase by carbamates or huperzine A increases residual activity of the enzyme upon soman challenge.
Eckert S; Eyer P; Worek F
Toxicology; 2007 Apr; 233(1-3):180-6. PubMed ID: 17097792
[TBL] [Abstract][Full Text] [Related]
12. Physostigmine reverses cognitive dysfunction caused by moderate hypoxia in adult mice.
Bekker A; Haile M; Gingrich K; Wenning L; Gorny A; Quartermain D; Blanck T
Anesth Analg; 2007 Sep; 105(3):739-43. PubMed ID: 17717233
[TBL] [Abstract][Full Text] [Related]
13. [Huperzine a: an acetylcholinesterase inhibitor with high pharmacological potential].
Pilotaz F; Masson P
Ann Pharm Fr; 1999 Sep; 57(5):363-73. PubMed ID: 10520506
[TBL] [Abstract][Full Text] [Related]
14. The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques.
Malkova L; Kozikowski AP; Gale K
Neuropharmacology; 2011 Jun; 60(7-8):1262-8. PubMed ID: 21185313
[TBL] [Abstract][Full Text] [Related]
15. Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases.
Saxena A; Qian N; Kovach IM; Kozikowski AP; Pang YP; Vellom DC; Radić Z; Quinn D; Taylor P; Doctor BP
Protein Sci; 1994 Oct; 3(10):1770-8. PubMed ID: 7849595
[TBL] [Abstract][Full Text] [Related]
16. Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment.
Xiong ZQ; Tang XC; Lin JL; Zhu DY
Zhongguo Yao Li Xue Bao; 1995 Jan; 16(1):21-5. PubMed ID: 7771190
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic administration of huperzine A on memory in guinea pigs.
Filliat P; Foquin A; Lallement G
Drug Chem Toxicol; 2002 Feb; 25(1):9-24. PubMed ID: 11850973
[TBL] [Abstract][Full Text] [Related]
18. [Studies on analogues of huperzine A for treatment of senile dementia. VI. Asymmetric total synthesis of 14-nor-huperzine A and its inhibitory activity of acetylcholinesterase].
He XC; Yu GL; Bai DL
Yao Xue Xue Bao; 2003 May; 38(5):346-9. PubMed ID: 12958837
[TBL] [Abstract][Full Text] [Related]
19. Effects of synthetic (-)-huperzine A on cholinesterase activities and mouse water maze performance.
Liu J; Zhang HY; Tang XC; Wang B; He XC; Bai DL
Zhongguo Yao Li Xue Bao; 1998 Sep; 19(5):413-6. PubMed ID: 10375798
[TBL] [Abstract][Full Text] [Related]
20. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice.
Ohba T; Yoshino Y; Ishisaka M; Abe N; Tsuruma K; Shimazawa M; Oyama M; Tabira T; Hara H
Biosci Biotechnol Biochem; 2015; 79(11):1838-44. PubMed ID: 26059088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
